Symbols

NMTC

NeuroOne Medical·NASDAQ

--(--)

NMTC fundamentals

NMTC Q3 2025 Earnings

NeuroOne Medical (NMTC) released its earnings on Aug 14, 2025: revenue was 1.70M (YoY +105.87%), missed estimates; EPS was -0.03 (YoY +70.00%), missed estimates.

Revenue / YoY

1.70M

+105.87%

EPS / YoY

-0.03

+70.00%

Report date

Aug 14, 2025

NMTC Earnings Call Summary for Q3,2025

Revenue Surge: Q3 product revenue up 105% to $1.7 million, with full-year guidance of $8-10 million (132%-190% YoY growth).
Margin Expansion: Gross margin improved to 53.9%, with updated FY2025 target of 50-53%.
Patient Success: First patient achieved 1-year seizure freedom, highlighting OneRF's clinical impact.
New Markets: FDA 510(k) submitted for trigeminal neuralgia, and SCS electrode design targeting $3B lower back pain market.
Financial Strength: Debt-free with $8 million cash, $8.2 million raised in April, and 46% net loss improvement.

Earnings

EPS

Revenue

Revenue & Expenses

NMTC has released its 2025 Q3 earnings report, with revenue of 1.70M, reflecting a YoY change of 105.39%, and net profit of -1.50M, showing a YoY change of 45.77%. The Sankey diagram below clearly presents NMTC's revenue sources and cost distribution.

Key Indicators

NeuroOne Medical (NMTC) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

NeuroOne Medical (NMTC)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

NeuroOne Medical (NMTC)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

NeuroOne Medical (NMTC)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown